JNJ-18038683

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Herbert Meltzer, King's College London

Conditions

Bipolar DisorderMajor Depressive Disorder

Phase 2

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

CompletedNCT00566202

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Major Depressive Disorder

Start: 2007-12-31End: 2008-12-31Updated: 2014-08-06

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

CompletedNCT02466685

Herbert MeltzerBipolar Disorder

Start: 2015-09-30End: 2022-12-31Updated: 2023-11-14

Unknown Phase

Imaging 5HT7 Antagonist Effects in Bipolar Disorder

King's College LondonBipolar Disorder

Start: 2018-08-16End: 2022-06-30Target: 68Updated: 2021-09-08